SpectraCure has filed for a new patent to the European Patent Office, the patent covers a new technology to improve the company's IDOSE technology. The IDOSE technique is at the heart of the company's method of treating prostate cancer with photodynamic therapy (PDT). In short, the technique implies that the prostate tissue is monitored during treatment with a series of different measurements to ensure that the correct dose is given so that the tumor is eliminated but healthy surrounding tissue is not damaged.
"The precision of IDOSE is already very good," comments SpectraCure's CTO Johannes Swartling. “However, we are always working on developing improvements that lead to even better precision, especially in situations that are difficult to predict and that may arise during treatment. For example, bleeding tissue that could affect how the laser light from our equipment is conducted into the tissues. The new technology that we are now seeking for patent protection can detect and compensate for such bleeding in a better way than before.”
No new hardware needs to be introduced into SpectraCure's equipment to use the new technology, the improvement can be made in the existing equipment with an upgrade of the software.
The patent application has first been submitted to the European Patent Office, and after examination it will be transferred to the PCT phase, which is a way to coordinate patent reviews for all the world's countries.
